MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk.

Slides:

Advertisements

Similar presentations

MYC/BCL2 protein coexpression contributes inferior outcome in DLBCL

Advertisements

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

MYC-associated and Double Hit Lymphomas

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma by Anamarija M. Perry, Teresa.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma Kun-Ming Chung, Sheng-Tsung Chang,

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Double hit lymphomas What are they and how should they be managed?

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

Superior Survival after Autologous vs

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

by Juliette J. Hoefnagel, Remco Dijkman, Katia Basso, Patty M

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric.

A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma by Lisa Giulino, Susan Mathew, Gianna Ballon, Amy Chadburn, Sharon Barouk, Giuseppina.

Jonathan W. Friedberg M.D., M.M.Sc.

NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes by Friedrich.

A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays P. Mickey Williams, Rui Li, Nathalie A.

PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma by Michela Boi, Andrea Rinaldi, Ivo Kwee, Paola Bonetti, Maria Todaro, Fabrizio.

by Fangxin Hong, Thomas M Habermann, Leo I

A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros

TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma by David W. Scott, Karen L. Mungall, Susana Ben-Neriah, Sanja Rogic, Ryan D.

Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens Christopher D. Carey, Daniel.

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue by David W. Scott,

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano,

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation Yi-Shan.

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma by Hanne Due, Anna Amanda Schönherz,

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy by Wyndham H. Wilson, Michael L. Grossbard,

PD-L1 and tumor-associated macrophages in de novo DLBCL

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

by Pierre Sesques, and Nathalie A. Johnson

Rituximab immunotherapy: it’s getting personal

Relationship of PMBL to Hodgkin lymphoma.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

Optimizing therapy for nodal marginal zone lymphoma

How I treat T-cell acute lymphoblastic leukemia in adults

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Outcomes in patients with PTCL

Presentation transcript:

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program by Shimin Hu, Zijun Y. Xu-Monette, Alexander Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, Carlo Visco, Yong Li, Roberto N. Miranda, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W. L. Choi, Xiaoying Zhao, J. Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Ai, Maurilio Ponzoni, Andrés J. M. Ferreri, Fan Zhou, Graham W. Slack, Randy D. Gascoyne, Meifeng Tu, Daina Variakojis, Weina Chen, Ronald S. Go, Miguel A. Piris, Michael B. Møller, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 121(20):4021-4031 May 16, 2013 ©2013 by American Society of Hematology

Prognostic impact of MYC/BCL2 coexpression in DLBCL Prognostic impact of MYC/BCL2 coexpression in DLBCL. (A-B) OS (A) and PFS (B) of patients with DLBCL with MYC/BCL2 coexpression (MYC+BCL2+) in the training set. Prognostic impact of MYC/BCL2 coexpression in DLBCL. (A-B) OS (A) and PFS (B) of patients with DLBCL with MYC/BCL2 coexpression (MYC+BCL2+) in the training set. (C-D) OS of patients with MYC+ DLBCL in the presence (C) or absence (D) of BCL2 coexpression in the training set. (E-F) OS of patients with BCL2+ DLBCL in the presence (E) or absence (F) of MYC coexpression in the training set. Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology

Prognostic impact of MYC/BCL2 coexpression in DLBCL risk-stratified according to clinicopathologic parameters. Prognostic impact of MYC/BCL2 coexpression in DLBCL risk-stratified according to clinicopathologic parameters. (A-B) OS (A) and PFS (B) of patients with MYC+BCL2+ DLBCL of the GCB subtype in the training set. (C-D) OS (C) and PFS (D) of patients with MYC+BCL2+ DLBCL of the ABC subtype in the training set. (E-F) OS (E) and PFS (F) of patients with MYC+BCL2+ DLBCL risk-stratified according to IPI risk scores in the training set. DP, MYC/BCL2 double-positive; Non-DP, non–double positive. Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology

Frequency of BCL2 and MYC expression in COO subtypes of DLBCL Frequency of BCL2 and MYC expression in COO subtypes of DLBCL. (A) Relative frequency of the ABC vs GCB subtype in DLBCL positive for BCL2 expression, MYC expression, or MYC/BCL2 coexpression in the training set. Frequency of BCL2 and MYC expression in COO subtypes of DLBCL. (A) Relative frequency of the ABC vs GCB subtype in DLBCL positive for BCL2 expression, MYC expression, or MYC/BCL2 coexpression in the training set. (B) Frequency of BCL2 expression, MYC expression, or MYC/BCL2 coexpression (in the presence or absence of MYC/BCL2 corearrangements, DH) in DLBCL of the ABC and GCB subtypes in the training set. DH, double hit. Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology

MYC/BCL2 coexpression contributes to the inferior prognosis of ABC-DLBCL. MYC/BCL2 coexpression contributes to the inferior prognosis of ABC-DLBCL. (A-B) OS (A) and PFS (B) of the ABC vs GCB subtype of DLBCL in the entire training set. COO classification of 411 cases was based on GEP results and 55 cases based on IHC results. (C-D) OS (C) and PFS (D) of the ABC vs GCB subtype of DLBCL after all MYC+BCL2+ cases were excluded. (E-F) OS (E) and PFS (F) of the ABC vs GCB subtype in MYC+BCL2+ DLBCL. Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology

Prognostic impact of MYC/BCL2 coexpression in DLBCL is independent of MYC/BCL2 corearrangement and TP53 mutation status. Prognostic impact of MYC/BCL2 coexpression in DLBCL is independent of MYC/BCL2 corearrangement and TP53 mutation status. (A-B) OS (A) and PFS (B) of patients with MYC/BCL2 double-hit DLBCL. (C-D) OS (C) and PFS (D) of patients with MYC+BCL2+ DLBCL in the absence of MYC/BCL2 double hit. (E) OS of patients with MYC+BCL2+ DLBCL in the absence of TP53 mutation. (F) Prognostic impact of TP53 mutation in MYC+BCL2+ DLBCL. Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology

MYC/BCL2 coexpression contributes to the different gene expression profiles between GCB and ABC subtypes of DLBCL. (A) GEP comparison between the ABC vs GCB subtype of DLBCL with MYC/BCL2 coexpression. MYC/BCL2 coexpression contributes to the different gene expression profiles between GCB and ABC subtypes of DLBCL. (A) GEP comparison between the ABC vs GCB subtype of DLBCL with MYC/BCL2 coexpression. Of 157 cases of MYC+BCL2+ DLBCL, GEP was successfully performed in 149 cases (ABC: 102; GCB: 47). DP, MYC/BCL2 double positive. A total of 208 genes corresponding to 365 probe sets were differentially expressed (P < .001). (B) GEP comparison between the ABC (30 cases) vs GCB (58 cases) subtype of DLBCL negative for both MYC and BCL2 protein expression. A total of 20 genes corresponding to 30 probesets were differentially expressed between the 2 COO subtypes (P < .01). DN, MYC/BCL2 double negative. Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology

Gene expression signature of DLBCL with MYC/BCL2 coexpression. Gene expression signature of DLBCL with MYC/BCL2 coexpression. Comparison of GEPs of DLBCL with MYC/BCL2 coexpression (149 cases) vs DLBCL negative for MYC and BCL2 expression (88 cases). A total of 153 genes corresponding to 219 probe sets were differentially expressed (P < .001). Shimin Hu et al. Blood 2013;121:4021-4031 ©2013 by American Society of Hematology